2017-02

SNOT-22 in a control population

Erskine, SE

http://hdl.handle.net/10026.1/4637

10.1111/coa.12667

Clinical Otolaryngology

Wiley

All content in PEARL is protected by copyright law. Author manuscripts are made available in accordance with publisher policies. Please cite only the published version using the details provided on the item record or document. In the absence of an open licence (e.g. Creative Commons), permissions for further reuse of content should be sought from the publisher or author.
SNOT 22 in a Control Population

The CRES Group

Sally Erskine¹,*, Carl Philpott¹,²,²²,²³, Allan Clark, Steve Morris²¹, Claire Hopkins², Alasdair Robertson⁴, Shahzada Ahmed⁶, Naveed Kara¹², Sean Carrie¹¹, Vishnu Sunkaraneni²⁰, Jaydip Ray¹⁷, Shahram Anari⁷, Paul Jervis¹⁰, Jaan Panesaar¹⁸, Amir Farboud⁵, Nimal Kumar³, Russell Cathcart⁸, Robert Almeyda¹⁴, Hisham Khalil⁹, Peter Prinsley¹³, Nicolas Mansell¹⁵, Mahmoud Salam¹⁶, Jonathan Hobson¹⁹, Jane Woods¹ and Emma Coombes

Aim:
To assess SNOT-22 and its subscales in a healthy UK wide population

Methodology/Principle
This analysis uses data from the ‘Chronic Rhinosinusitis Epidemiology Study’ (CRES) which recruited from 30 centres across the UK, and the ‘Characterising the sinusitis population: The socioeconomic impact of Chronic Rhinosinusitis Study’ (SocCoR). 250 healthy volunteers were recruited as part of these studies. Study-specific questionnaires including demographics, socioeconomic factors and past medical history as well as SNOT-22 and SF-36 were distributed. The healthy population (controls) had no self-reported nasal problems in the past, no chronic conditions undergoing active treatment and no hospital admissions in the preceding 12 months.

Results:
The mean SNOT-22 total score overall was 12.0. The mean was 10.2 for males with a median of 6.5, and a mean of 13.2 for females with a median of 9. Females scored significantly more highly than males on the sleep/fatigue and facial domains.
Conclusions

Differences in SNOT-22 scores were identified between those with different types of CRS with those with CRSwNPs /AFRS having significantly higher scores in the nasal domain compared to those without polyps.

Introduction

Chronic rhinosinusitis (CRS) affects a significant proportion of the population; a recent European study found a prevalence of 11% (Hastan, Fokkens et al. 2011). Patient reported outcome measures (PROMs) are a means of collecting information on the effectiveness of care delivered to patients as perceived by the patients themselves and are increasingly important in clinical practice and in research (Timmins 2008; HaSCI 2014) (Greenhalgh, Long et al. 2005) on a background of increasing costs of healthcare across the world. The most widely accepted and best validated patient self-report symptom evaluation tool for use in CRS is the SNOT-22, whose 22 items incorporate both nasal and non-nasal symptoms(Hopkins, Gillett et al. 2009). Within SNOT-22, self-reported symptom severity is graded from 0-5, with 5 being a severe problem. It is a modification of the 31-question Rhinosinusitis Outcome Measure (RSOM-31)(Piccirillo, Edwards et al. 1995). Factor analysis identifies four principal SNOT domains – nasal, facial, sleep and mood (Browne, Hopkins et al. 2007) (Lange, Thilsing et al. 2011; Lange, Holst et al. 2013; DeConde, Mace et al. 2014). Factor analysis for SNOT-22 was validated in a Danish population of 40 patients (Lange, Thilsing et al. 2011).The four subscales are rhinological symptoms (questions 1-5, 7and 8), ear and facial symptoms (questions 9-12), sleep function (questions 13-15) and psychological issues (questions 17-22). The questions regarding cough and waking up tired were not included in these subscales. There are few data for ‘normal’ non-CRS patients, particularly in the UK population.
The overarching aim of the Chronic Rhinosinusitis Epidemiology Study (CRES) was to aid better understanding of medical and non-medical factors contributing to development or worsening of CRS. The aim of SocCoR was to identify the socio-economic costs of CRS to improve the understanding of the impact of CRS disease to the patient and the NHS. The purpose of this analysis was to yield large dataset of SNOT-22 information for a control population in the UK.

**Materials and Methods**

CRES was conducted as a cross-sectional cohort study and recruited from a total of 30 sites from around the UK (including the devolved nations of Wales and Scotland), between 2007 and 2013. Controls included family and friends of those attending ENT outpatient clinics and hospital staff who had no diagnosis of persistent nose or sinus problems and had not been admitted to hospital in the previous 12 months. Questionnaires were returned by participants using a Freepost envelope and scanned to a secure database using Formic. Two members of the research team checked the accuracy of electronic scanning of returned questionnaires. SocCoR recruited participants meeting the same criteria, but only from one site.

The CRES was approved by the Oxford C Research Ethics Committee, sponsored by the University of East Anglia (UEA) and funded by the Anthony Long and Bernice Bibby Trusts. The study specific questionnaire was anonymous and therefore no consent was taken but implied through participation. Participant information leaflets were provided.

**Results**

A total of 251 healthy volunteers completed the SNOT-22 questionnaire.
Table 1: SNOT-22 and its subscales

<table>
<thead>
<tr>
<th></th>
<th>n</th>
<th>Age (range)</th>
<th>SNOT-22</th>
<th>Nasal</th>
<th>Facial</th>
<th>Sleep fatigue</th>
<th>Emotional</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>mean (sd)</td>
<td>Median (IQR)</td>
<td>mean (sd)</td>
<td>mean (sd)</td>
<td>mean (sd)</td>
</tr>
<tr>
<td></td>
<td>Total</td>
<td>251</td>
<td>47.5 (19-80)</td>
<td>12.0 (13.6)</td>
<td>8 (2-17)</td>
<td>2.5 (4.0)</td>
<td>1.1 (2.5)</td>
</tr>
<tr>
<td></td>
<td>Females</td>
<td>143</td>
<td>46.8 (14.4)</td>
<td>13.2 (15.0)</td>
<td>9 (2-18)</td>
<td>2.3 (3.6)</td>
<td>1.4 (2.9)</td>
</tr>
<tr>
<td></td>
<td>Males</td>
<td>96</td>
<td>48.8 (15.8)</td>
<td>10.2 (11.1)</td>
<td>6.5 (2-14.5)</td>
<td>2.8 (4.4)</td>
<td>0.7 (1.4)</td>
</tr>
<tr>
<td>Differences (p values)</td>
<td></td>
<td>0.092(^1)</td>
<td>0.297(^2)</td>
<td>0.363(^2)</td>
<td>0.006(^3)</td>
<td>0.005(^3)</td>
<td>0.193(^1)</td>
</tr>
</tbody>
</table>

\(^1\)t-test (unequal variances); \(^2\) t-test (equal variances); \(^3\) Mann-Whitney test
Boxplot to show SNOT-22 for males and females
Females tended to score more highly than males overall. They also had a wider range of scores. Females scored more highly on each of the domains; this was statistically significant within the sleep fatigue and facial domains.

No association was found between SNOT-22 score and age (TBC).

Discussion

Our data describe a large population of healthy volunteers from across the UK. We found a mean SNOT-22 score of 10.2 for males with a median of 6.5, and a mean of 13.2 for females with a median of 9. The standard deviation was higher amongst females. Our control results were not normally distributed; this is to be expected since there should be a large number of individuals who score very low (floor effect). Previous studies of a healthy control population have found a median of 7-9 (Gillett, Hopkins et al. 2009; Gregório, Andrade et al. 2015). The population (n=116) recruited by Gillett et al included a higher proportion of males and also those recruited through a tennis club who may have
been healthier than the general population. A study using a random sample of the Danish population (n=271 for those without CRS) similarly found a median SNOT-22 value of 7 (IQR2-15), (Lange, Holst et al. 2013; Lange, Thilsing et al. 2015); they do not differentiate by gender. In a study of 539 healthy volunteers in Sao Paulo, Gregorio et al also found SNOT-22 scores were distributed significantly differently between men and women. Men presented significantly lower normal values than women (men: mean = 8.58 and median = 7 versus women: mean = 10.94 and median = 9;p = 0.005). A median score of 7-10 for males and 9-13 for females therefore appears to be reproducible benchmark for ‘normal’ SNOT-22. This should not be used as an ‘absolute’ normal score to assign care for CRS or as a diagnostic threshold, but is a useful figure to consider when assessing SNOT-22 in the context of CRS in both clinic and research.

Conclusion

Our data provide reference data for scores across SNOT-22 in a healthy population across a wide cross section of the UK population and they demonstrate the differences in reporting in males and females. These data can be used in future studies for comparison with different disease populations with rhinosinusitis.

Acknowledgments

Jane Woods


